Sep. 20 at 1:57 AM
$KTTA is sitting near rock bottom with a tiny market cap, low float, and recent catalysts that could spark a massive re-rating. The company is advancing its PAS-004 clinical trial, expanding internationally, and strengthening its scientific advisory board signaling real biotech momentum. Trading under
$1 with a prior high near
$7.50, KTTA is deeply undervalued and positioned for asymmetric upside. If trial data surprises, volume surges, and sentiment shifts, this could be one of those rare small-cap biotech names that climbs back into the
$20–
$50+ range over time.